Neurovascular Unit Function Assessment in Parkinson's Disease

Neurovascular Unit Function Assessment in Parkinson's Disease

Study Overview

Study Name: NVU-PD-001 - Neurovascular Unit Function Assessment in Parkinson's Disease

Study Type: Prospective Clinical Cohort Study with Mechanistic Correlates

Primary Objective: To characterize blood-brain barrier (BBB) integrity and neurovascular unit (NVU) function in Parkinson's disease patients compared to healthy controls, and to correlate NVU dysfunction with disease severity, progression, and molecular biomarkers.

Background and Rationale

Neurovascular Unit Function Assessment in Parkinson's Disease

Study Overview

Study Name: NVU-PD-001 - Neurovascular Unit Function Assessment in Parkinson's Disease

Study Type: Prospective Clinical Cohort Study with Mechanistic Correlates

Primary Objective: To characterize blood-brain barrier (BBB) integrity and neurovascular unit (NVU) function in Parkinson's disease patients compared to healthy controls, and to correlate NVU dysfunction with disease severity, progression, and molecular biomarkers.

Background and Rationale

The Neurovascular Unit in Neurodegeneration

The neurovascular unit (NVU) hypothesis proposes that BBB dysfunction represents a critical upstream mechanism in PD pathogenesis. The BBB is the selective barrier separating the peripheral circulation from the central nervous system, maintained by the coordinated function of endothelial cells, pericytes, astrocytes, and neurons.

NVU components:

• Endothelial cells: Form the physical barrier with tight junctions (claudin-5, occludin, ZO-1)
• Pericytes: Regulate capillary blood flow, BBB development, and endothelial function
• Astrocytes: Form the glia limitans, provide metabolic support, regulate extracellular potassium
• Neurons: Coordinate neurovascular coupling, receive blood-borne signals

BBB Dysfunction in Parkinson's Disease

Multiple lines of evidence implicate BBB dysfunction in PD pathogenesis:

Neuropathological evidence:

• Reduced tight junction proteins (occludin, claudin-5) in PD substantia nigra
• Pericyte loss and reduced pericyte coverage in PD brains
• Leakage of plasma proteins into PD brain parenchyma
• Accumulation of peripheral immune cells in PD substantia nigra

• MRI with gadolinium shows enhanced permeability in PD brain regions
• DCE-MRI demonstrates increased K^trans (volume transfer constant) in PD
• DTI-ALPS (diffusion tensor imaging along the perivascular space) shows glymphatic dysfunction

• Elevated CSF/serum albumin ratio indicating BBB leakage
• Increased CSF levels of BBB-associated proteins (s100b, GFAP)
• Altered levels of pericyte markers (PDGFR-beta, RBP4) in CSF

NVU Dysfunction and Alpha-Synuclein Pathology

The relationship between NVU dysfunction and alpha-synuclein pathology is bidirectional:

BBB dysfunction promoting aggregation:

• Impaired clearance of extracellular alpha-synuclein
• Reduced glymphatic function for interstitial solute removal
• Increased entry of peripheral pro-inflammatory factors

• Direct toxicity to endothelial cells and pericytes
• Disruption of tight junction proteins
• Activation of MMPs (matrix metalloproteinases) degrading basement membrane

• High metabolic demand makes SNc neurons especially dependent on adequate blood supply
• Impaired blood flow may compound the vulnerability of these neurons

Study Design

Study Population

| Group | Sample Size | Inclusion Criteria |
|-------|-------------|---------------------|
| PD Patients | n=120 | Idiopathic PD, H&Y 1-3, Age 50-80 |
| Healthy Controls | n=60 | Age-matched, no neurological disease |

Eligibility Criteria

Inclusion (PD):

• Diagnosis of idiopathic Parkinson's disease per UK Brain Bank criteria
• Hoehn & Yahr stage 1-3
• Disease duration 1-10 years
• MMSE >= 24

• Secondary parkinsonism
• Active infection or inflammatory disease
• Prior anti-TNF or immunomodulatory therapy
• Contraindications to MRI or gadolinium contrast

Endpoints

Primary Endpoints

| Endpoint | Method | Timepoint |
|----------|--------|-----------|
| BBB permeability | DCE-MRI (K^trans) | Baseline, 12 months |
| CSF albumin ratio | Lumbar puncture | Baseline |
| Tight junction protein expression | CSF ELISA | Baseline |

Secondary Endpoints

| Endpoint | Method | Timepoint |
|----------|--------|-----------|
| Pericyte coverage | RBP4/PDGFR-beta (CSF) | Baseline, 12 months |
| Neurofilament light chain (NfL) | Plasma | Baseline, 6, 12, 24 months |
| Alpha-synuclein seeding | RT-QuIC (CSF) | Baseline |
| Disease progression | MDS-UPDRS | Baseline, 6, 12, 24 months |
| Cognitive function | MoCA | Baseline, 12, 24 months |
| Cerebral blood flow | ASL-MRI | Baseline, 12 months |

Exploratory Endpoints

• Glymphatic function assessment (diffusion MRI)
• Gut permeability markers (serum zonulin, LBP)
• Peripheral inflammatory cytokines
• Metabolomic profiling

Methods

Neuroimaging Protocol

DCE-MRI (Dynamic Contrast-Enhanced MRI):

• Sequence: 3D T1-weighted GRE
• TR/TE: 5/2 ms
• Flip angle: 15 degrees
• Spatial resolution: 1x1x3 mm
• Temporal resolution: 5 seconds
• Contrast agent: Gd-DTPA (0.1 mmol/kg)
• Regions of interest: substantia nigra, striatum, frontal cortex, hippocampus

• Sequence: PASL or pCASL
• Labeling duration: 1.5 seconds
• Post-labeling delay: 1.5 seconds
• Whole-brain coverage
• CBF quantification in ml/100g/min

• Method for assessing glymphatic function
• Measures diffusivity along perivascular spaces in lateral ventricles
• Reduced ALPS index indicates impaired glymphatic function

CSF Collection and Analysis

Lumbar puncture (optional, target n=60):

• CSF collected at baseline and 12-month visits
• Aliquoted for biomarker analysis
• Stored at -80 degrees C

• Albumin (CSF and serum for ratio calculation)
• Tight junction proteins: claudin-5, occludin, ZO-1 (ELISA)
• Pericyte markers: PDGFR-beta, RBP4
• Neurodegeneration markers: NfL, alpha-synuclein, tau

Statistical Analysis

Sample Size Justification

Based on expected effect size of d=0.5 for K^trans in substantia nigra between PD and controls:

• Alpha = 0.05 (two-sided)
• Power = 80%
• n=120 PD, n=60 controls provides adequate power

Primary Analysis

Risk Assessment

| Risk | Severity | Mitigation |
|------|----------|------------|
| MRI adverse events | Low | Screen for contraindications |
| Gadolinium deposition | Low | Use macrocyclic agents, limit repeat |
| Lumbar puncture | Moderate | Standard sterile technique |
| Blood draw | Minimal | Standard phlebotomy |

Budget Estimate

| Item | Cost ($) |
|------|----------|
| DCE-MRI (120 subjects x 2) | 240,000 |
| ASL-MRI (120 subjects x 2) | 120,000 |
| CSF analysis (60 subjects) | 30,000 |
| Biomarker assays | 60,000 |
| Clinical assessments | 40,000 |
| Personnel | 150,000 |
| Indirect costs | 160,000 |
| Total | 800,000 |

Related Pages

• [Neurovascular Unit Dysfunction Hypothesis](/hypotheses/neurovascular-unit-parkinsons)
• [Glymphatic-Circadian Axis Experiment](/experiments/glymphatic-circadian-axis-parkinsons)
• [PD Biomarker Discovery Study](/experiments/pd-biomarker-discovery)
• [BBB Transport Mechanisms](/mechanisms/bbb-transport-mechanisms)

References